Advertisement

Multiple Stakeholder Perspectives on the Reinvigorated Case for Kidney Disease Screening

      The United States Preventive Services Task Force has no current recommendation to guide primary care physician screening for chronic kidney disease (CKD). This is misaligned with the scope of the CKD public health emergency, recommendations from clinical practice guidelines, health spending on CKD, the changing landscape of CKD detection and treatment, and the focus by policymakers on identifying tangible approaches to improving health equity. This review summarizes patient, clinician, health equity, and health system perspectives in support of screening adults with risk factors for CKD. This review concludes with the assessment that the United States Preventive Services Task Force should revisit targeted CKD screening specifically for adults with diabetes and/or hypertension.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Chronic Kidney Disease in the United States, 2021. U.S. Department of Health and Human Services Centers for Disease Control and Prevention.
        • United States Renal Data System
        2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States.
        National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD2020
        • Moyer V.A.
        Screening for chronic kidney disease: U.S. Preventive services Task Force recommendation statement.
        Ann Intern Med. 2012; 157: 567
        • Peralta C.A.
        • Frigaard M.
        • Rolon L.
        • et al.
        Screening for CKD to improve Processes of care among Nondiabetic veterans with hypertension: a pragmatic cluster-randomized trial.
        Clin J Am Soc Nephrol. 2020; 15: 174-181
        • Carroll J.K.
        • Pulver G.
        • Dickinson L.M.
        • et al.
        Effect of 2 clinical decision support Strategies on chronic kidney disease outcomes in primary care: a cluster randomized trial.
        JAMA Netw Open. 2018; 1: e183377
        • Medder J.D.
        • Kahn N.B.
        • Susman J.L.
        Risk factors and recommendations for 230 adult primary care patients, based on U.S. Preventive Services Task Force guidelines.
        Am J Prev Med. 1992; 8: 150-153
        • Yarnall K.S.H.
        • Pollak K.I.
        • Østbye T.
        • Krause K.M.
        • Michener J.L.
        Primary care: is there Enough time for prevention?.
        Am J Public Health. 2003; 93: 635-641
        • Taal M.W.
        Screening for chronic kidney disease: preventing harm or harming the Healthy?.
        Plos Med. 2012; 9: e1001345
        • Moreno J.A.
        • Martin-Cleary C.
        • Gutierrez E.
        • et al.
        Haematuria: the forgotten CKD factor?.
        Nephrol Dial Transpl. 2012; 27: 28-34
        • Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group
        KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.
        Kidney Int Suppl. 2013; 3: 1
        • American Diabetes Association
        Microvascular complications and Foot care: Standards of medical Care in diabetes—2021.
        Diabetes Care. 2021; 44: S151-S167
        • Williams B.
        • Mancia G.
        • Spiering W.
        • et al.
        2018 ESC/ESH Guidelines for the management of arterial hypertension.
        Eur Heart J. 2018; 39: 3021-3104
        • Whelton P.K.
        • Carey R.M.
        • Aronow W.S.
        • et al.
        2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        Hypertension. 2018; 71: e13-e115
        • Matsushita K.
        • Jassal S.K.
        • Sang Y.
        • et al.
        Incorporating kidney disease measures into cardiovascular risk prediction: Development and validation in 9 million adults from 72 datasets.
        EClinicalMedicine. 2020; 27: 100552
        • Gaitonde D.Y.
        • Cook D.L.
        • Rivera I.M.
        Chronic kidney disease: detection and evaluation.
        Am Fam Physician. 2017; 96: 776-783
        • Tangri N.
        • Grams M.E.
        • Levey A.S.
        • et al.
        Multinational assessment of Accuracy of equations for predicting risk of kidney failure: a Meta-analysis.
        JAMA. 2016; 315: 164-174
        • Heerspink H.J.L.
        • Stefánsson B.V.
        • Correa-Rotter R.
        • et al.
        Dapagliflozin in patients with chronic kidney disease.
        N Engl J Med. 2020; 383: 1436-1446
        • Perkovic V.
        • Jardine M.J.
        • Neal B.
        • et al.
        Canagliflozin and renal outcomes in type 2 diabetes and Nephropathy.
        N Engl J Med. 2019; 380: 2295-2306
        • Bakris G.L.
        • Agarwal R.
        • Anker S.D.
        • et al.
        Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes.
        N Engl J Med. 2020; 383: 2219-2229
      2. Kidney health evaluation measure. National kidney Foundation.
      3. Health disparities among aged ESRD beneficiaries, 2014.
        • Muntner P.
        • Hardy S.T.
        • Fine L.J.
        • et al.
        Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018.
        JAMA. 2020; 324: 1190
        • Tummalapalli S.L.
        • Powe N.R.
        • Keyhani S.
        Trends in quality of care for patients with CKD in the United States.
        Clin J Am Soc Nephrol. 2019; 14: 1142-1150
        • Eberly L.A.
        • Yang L.
        • Eneanya N.D.
        • et al.
        Association of race/Ethnicity, gender, and socioeconomic status with sodium-glucose Cotransporter 2 inhibitor Use among patients with diabetes in the US.
        JAMA Netw Open. 2021; 4: e216139
      4. Medicare Advantage Plans Offering Expanded Supplemental Benefits. February 10. Commonwealth Fund, New York, NY2021
        • Delgado C.
        • Baweja M.
        • Crews D.C.
        • et al.
        A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease.
        Am J Kidney Dis. 2021; 79: 268-288https://doi.org/10.1053/j.ajkd.2021.08.003
        • Alfego D.
        • Ennis J.
        • Gillespie B.
        • et al.
        Chronic kidney disease testing among at-risk adults in the U.S. remains low: real-world evidence from a national laboratory database.
        Diabetes Care. 2021; 44: 2025-2032
        • Hoerger T.J.
        • Wittenborn J.S.
        • Segel J.E.
        • et al.
        A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening.
        Am J Kidney Dis Off J Natl Kidney Found. 2010; 55: 463-473
        • Vassalotti J.A.
        • DeVinney R.
        • Lukasik S.
        • et al.
        CKD quality improvement intervention with PCMH integration: health plan results.
        Am J Manag Care. 2019; 25: e326-e333
        • Narva A.
        Population health for CKD and diabetes: Lessons from the Indian health service.
        Am J Kidney Dis Off J Natl Kidney Found. 2018; 71: 407-411